FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Dacarbazine for Injection, USP
Status: Discontinuation
»Therapeutic Categories: Oncology

Teva Pharmaceuticals (New 06/21/2019)

Company Contact Information:
800-545-8800

Presentation Posting Date Related Information
200 mg (NDCs 0703-5075-01 and 0703-5075-03) 06/21/2019 This product discontinuation is a business related decision. Anticipated discontinuance time is first quarter of the year 2020.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English